Change in (18)F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment

BACKGROUND: Bevacizumab (BEV), a humanized monoclonal antibody, become a currently important chemotherapeutic option for the patients with recurrent glioma. The aim of this retrospective study is to investigate whether (18)F-Fluoromisonidazole (FMISO) PET have the potential to detect BEV-resistant g...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: Yamaguchi, Shigeru, Hirata, Kenji, Toyonaga, Takuya, Kobayashi, Kentaro, Ishi, Yukitomo, Motegi, Hiroaki, Kobayashi, Hiroyuki, Shiga, Tohru, Tamaki, Nagara, Terasaka, Shunsuke, Houkin, Kiyohiro
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2016
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5148016/
https://ncbi.nlm.nih.gov/pubmed/27936194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0167917
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller